Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Familial dysbetalipoproteinemia is characterized by hyperlipidemia, increases in beta-migrating, very low density lipoproteins (β-VLDL), and homozygosity for apolipoprotein E2 (apo E2). In this study, 3 patients with familial dysbetalipoproteinemia were treated with lovastatin, and kinetics for apolipoprotein B (apo B) were determined in control and drug treatment periods. Multicompartmental analyses of apo B kinetics in VLDL and in low density lipoproteins (LDL) were carried out. Lovastatin therapy generally lowered plasma concentrations of apo B and cholesterol in VLDL and LDL. The reductions in concentrations were due mainly to a decrease in transport (production) rates for these fractions. Indeed, the fractional clearance rate (FCR) for LDL-apo B was reduced during lovastatin therapy. The decreased transport rate for VLDL-apo B and LDL-apo B could have been due to an inhibition of the synthesis of lipoproteins containing apo B. An alternate explanation is that lovastatin promoted direct removal of a rapidly-catabolized fraction of VLDL-apo B that is a precursor for longer-lived lipoproteins in the circulation; this mechanism could decrease input rates of identifiable lipoprotein species and retard their clearance because of "saturation" of LDL receptors by more rapidly removed lipoproteins. Finally, both mechanisms, i.e., decreased production and increased clearance of lipoproteins, may have contributed to the fall in VLDL-apo B and LDL-apo B concentrations during lovastatin therapy.

Original languageEnglish (US)
Pages (from-to)131-143
Number of pages13
JournalAtherosclerosis
Volume70
Issue number1-2
DOIs
StatePublished - 1988

Fingerprint

Hyperlipoproteinemia Type III
Lovastatin
Apolipoproteins B
LDL Lipoproteins
Lipoproteins
Therapeutics
Apolipoprotein E2
IDL Lipoproteins
VLDL Cholesterol
LDL Receptors
Drug and Narcotic Control
Hyperlipidemias

Keywords

  • Apolipoproteinemia B
  • Dysbetalipoproteinemia
  • Lovastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lovastatin therapy in familial dysbetalipoproteinemia : Effects on kinetics of apolipoprotein B. / Vega, Gloria L; East, Cara; Grundy, Scott M.

In: Atherosclerosis, Vol. 70, No. 1-2, 1988, p. 131-143.

Research output: Contribution to journalArticle

@article{f1102370cc8240848439516a76639cc9,
title = "Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B",
abstract = "Familial dysbetalipoproteinemia is characterized by hyperlipidemia, increases in beta-migrating, very low density lipoproteins (β-VLDL), and homozygosity for apolipoprotein E2 (apo E2). In this study, 3 patients with familial dysbetalipoproteinemia were treated with lovastatin, and kinetics for apolipoprotein B (apo B) were determined in control and drug treatment periods. Multicompartmental analyses of apo B kinetics in VLDL and in low density lipoproteins (LDL) were carried out. Lovastatin therapy generally lowered plasma concentrations of apo B and cholesterol in VLDL and LDL. The reductions in concentrations were due mainly to a decrease in transport (production) rates for these fractions. Indeed, the fractional clearance rate (FCR) for LDL-apo B was reduced during lovastatin therapy. The decreased transport rate for VLDL-apo B and LDL-apo B could have been due to an inhibition of the synthesis of lipoproteins containing apo B. An alternate explanation is that lovastatin promoted direct removal of a rapidly-catabolized fraction of VLDL-apo B that is a precursor for longer-lived lipoproteins in the circulation; this mechanism could decrease input rates of identifiable lipoprotein species and retard their clearance because of {"}saturation{"} of LDL receptors by more rapidly removed lipoproteins. Finally, both mechanisms, i.e., decreased production and increased clearance of lipoproteins, may have contributed to the fall in VLDL-apo B and LDL-apo B concentrations during lovastatin therapy.",
keywords = "Apolipoproteinemia B, Dysbetalipoproteinemia, Lovastatin",
author = "Vega, {Gloria L} and Cara East and Grundy, {Scott M}",
year = "1988",
doi = "10.1016/0021-9150(88)90107-4",
language = "English (US)",
volume = "70",
pages = "131--143",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Lovastatin therapy in familial dysbetalipoproteinemia

T2 - Effects on kinetics of apolipoprotein B

AU - Vega, Gloria L

AU - East, Cara

AU - Grundy, Scott M

PY - 1988

Y1 - 1988

N2 - Familial dysbetalipoproteinemia is characterized by hyperlipidemia, increases in beta-migrating, very low density lipoproteins (β-VLDL), and homozygosity for apolipoprotein E2 (apo E2). In this study, 3 patients with familial dysbetalipoproteinemia were treated with lovastatin, and kinetics for apolipoprotein B (apo B) were determined in control and drug treatment periods. Multicompartmental analyses of apo B kinetics in VLDL and in low density lipoproteins (LDL) were carried out. Lovastatin therapy generally lowered plasma concentrations of apo B and cholesterol in VLDL and LDL. The reductions in concentrations were due mainly to a decrease in transport (production) rates for these fractions. Indeed, the fractional clearance rate (FCR) for LDL-apo B was reduced during lovastatin therapy. The decreased transport rate for VLDL-apo B and LDL-apo B could have been due to an inhibition of the synthesis of lipoproteins containing apo B. An alternate explanation is that lovastatin promoted direct removal of a rapidly-catabolized fraction of VLDL-apo B that is a precursor for longer-lived lipoproteins in the circulation; this mechanism could decrease input rates of identifiable lipoprotein species and retard their clearance because of "saturation" of LDL receptors by more rapidly removed lipoproteins. Finally, both mechanisms, i.e., decreased production and increased clearance of lipoproteins, may have contributed to the fall in VLDL-apo B and LDL-apo B concentrations during lovastatin therapy.

AB - Familial dysbetalipoproteinemia is characterized by hyperlipidemia, increases in beta-migrating, very low density lipoproteins (β-VLDL), and homozygosity for apolipoprotein E2 (apo E2). In this study, 3 patients with familial dysbetalipoproteinemia were treated with lovastatin, and kinetics for apolipoprotein B (apo B) were determined in control and drug treatment periods. Multicompartmental analyses of apo B kinetics in VLDL and in low density lipoproteins (LDL) were carried out. Lovastatin therapy generally lowered plasma concentrations of apo B and cholesterol in VLDL and LDL. The reductions in concentrations were due mainly to a decrease in transport (production) rates for these fractions. Indeed, the fractional clearance rate (FCR) for LDL-apo B was reduced during lovastatin therapy. The decreased transport rate for VLDL-apo B and LDL-apo B could have been due to an inhibition of the synthesis of lipoproteins containing apo B. An alternate explanation is that lovastatin promoted direct removal of a rapidly-catabolized fraction of VLDL-apo B that is a precursor for longer-lived lipoproteins in the circulation; this mechanism could decrease input rates of identifiable lipoprotein species and retard their clearance because of "saturation" of LDL receptors by more rapidly removed lipoproteins. Finally, both mechanisms, i.e., decreased production and increased clearance of lipoproteins, may have contributed to the fall in VLDL-apo B and LDL-apo B concentrations during lovastatin therapy.

KW - Apolipoproteinemia B

KW - Dysbetalipoproteinemia

KW - Lovastatin

UR - http://www.scopus.com/inward/record.url?scp=0023880277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023880277&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(88)90107-4

DO - 10.1016/0021-9150(88)90107-4

M3 - Article

C2 - 3162680

AN - SCOPUS:0023880277

VL - 70

SP - 131

EP - 143

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1-2

ER -